chlorthalidone has been researched along with Metabolic Syndrome in 7 studies
Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study was conducted to evaluate the vascular effects of chlorthalidone, a distal tubule-acting natriuretic agent, in hypertensive patients with nondiabetic metabolic syndrome, an insulin-resistant condition characterized by endothelial dysfunction and high risk for diabetes mellitus development." | 9.11 | Chlorthalidone improves endothelial-mediated vascular responses in hypertension complicated by nondiabetic metabolic syndrome. ( Del Prato, S; Dell'Omo, G; Pedrinelli, R; Penno, G, 2005) |
| "Experiments determined whether the combination of endothelin A (ETA) receptor antagonist [ABT-627, atrasentan; (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid] and a thiazide diuretic (chlorthalidone) would be more effective at lowering blood pressure and reducing renal injury in a rodent model of metabolic syndrome compared with either treatment alone." | 7.80 | Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome. ( Jeon, Y; Jin, C; Kleven, DT; Pollock, DM; Pollock, JS; White, JJ, 2014) |
| "We conducted a subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) to compare metabolic, cardiovascular, and renal outcomes in individuals assigned to initial hypertension treatment with a thiazide-like diuretic (chlorthalidone), a calcium channel blocker (CCB; amlodipine), or an ACE inhibitor (lisinopril) in nondiabetic individuals with or without metabolic syndrome." | 7.74 | Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent ( Baimbridge, C; Barzilay, J; Basile, J; Black, HR; Dart, RA; Davis, B; Marginean, H; Nwachuku, C; Thadani, U; Whelton, P; Wong, ND; Wright, JT, 2008) |
| "The study was conducted to evaluate the vascular effects of chlorthalidone, a distal tubule-acting natriuretic agent, in hypertensive patients with nondiabetic metabolic syndrome, an insulin-resistant condition characterized by endothelial dysfunction and high risk for diabetes mellitus development." | 5.11 | Chlorthalidone improves endothelial-mediated vascular responses in hypertension complicated by nondiabetic metabolic syndrome. ( Del Prato, S; Dell'Omo, G; Pedrinelli, R; Penno, G, 2005) |
| "Experiments determined whether the combination of endothelin A (ETA) receptor antagonist [ABT-627, atrasentan; (2R,3R,4S)-4-(1,3-benzodioxol-5-yl)-1-[2-(dibutylamino)-2-oxoethyl]-2-(4-methoxyphenyl)pyrrolidine-3-carboxylic acid] and a thiazide diuretic (chlorthalidone) would be more effective at lowering blood pressure and reducing renal injury in a rodent model of metabolic syndrome compared with either treatment alone." | 3.80 | Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome. ( Jeon, Y; Jin, C; Kleven, DT; Pollock, DM; Pollock, JS; White, JJ, 2014) |
| "We conducted a subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) to compare metabolic, cardiovascular, and renal outcomes in individuals assigned to initial hypertension treatment with a thiazide-like diuretic (chlorthalidone), a calcium channel blocker (CCB; amlodipine), or an ACE inhibitor (lisinopril) in nondiabetic individuals with or without metabolic syndrome." | 3.74 | Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent ( Baimbridge, C; Barzilay, J; Basile, J; Black, HR; Dart, RA; Davis, B; Marginean, H; Nwachuku, C; Thadani, U; Whelton, P; Wong, ND; Wright, JT, 2008) |
| "Chlorthalidone, 12." | 1.39 | Obesity and hypertension: It's about more than the numbers. ( Ferdinand, KC, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Goldenberg, R | 1 |
| Bell, A | 1 |
| Cheng, W | 1 |
| Fils-Aimé, N | 1 |
| Burrows, M | 1 |
| Blavignac, J | 1 |
| Parron, E | 1 |
| Barakat, M | 1 |
| Ferdinand, KC | 1 |
| Jin, C | 1 |
| Jeon, Y | 1 |
| Kleven, DT | 1 |
| Pollock, JS | 1 |
| White, JJ | 1 |
| Pollock, DM | 1 |
| Düsing, R | 1 |
| Dell'Omo, G | 1 |
| Penno, G | 1 |
| Del Prato, S | 1 |
| Pedrinelli, R | 1 |
| Black, HR | 2 |
| Davis, B | 1 |
| Barzilay, J | 2 |
| Nwachuku, C | 1 |
| Baimbridge, C | 2 |
| Marginean, H | 1 |
| Wright, JT | 2 |
| Basile, J | 1 |
| Wong, ND | 1 |
| Whelton, P | 1 |
| Dart, RA | 1 |
| Thadani, U | 1 |
| Harris-Haywood, S | 1 |
| Pressel, S | 1 |
| Bareis, CJ | 1 |
| Basile, JN | 1 |
| Dart, R | 1 |
| Gupta, AK | 1 |
| Hamilton, BP | 1 |
| Einhorn, PT | 1 |
| Haywood, LJ | 1 |
| Jafri, SZ | 1 |
| Louis, GT | 1 |
| Whelton, PK | 1 |
| Scott, CL | 1 |
| Simmons, DL | 1 |
| Stanford, C | 1 |
| Davis, BR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for chlorthalidone and Metabolic Syndrome
| Article | Year |
|---|---|
Chlorthalidone improves endothelial-mediated vascular responses in hypertension complicated by nondiabetic metabolic syndrome.
Topics: Antihypertensive Agents; Blood Pressure; Capillaries; Chlorthalidone; Diuretics; Endothelium, Vascul | 2005 |
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Black People; Chlorthalidone; Double-B | 2008 |
5 other studies available for chlorthalidone and Metabolic Syndrome
| Article | Year |
|---|---|
Real-world effectiveness of treatments for type 2 diabetes, hypercholesterolemia, and hypertension in Canadian routine care - Results from the CardioVascular and metabolic treatment in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry,
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Benzimidazoles; Canada; Cardiovascular Dise | 2020 |
Obesity and hypertension: It's about more than the numbers.
Topics: Antihypertensive Agents; Chlorthalidone; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug | 2013 |
Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Antihypertensive Agents; Arterial Pressure; Atrasentan; Cell A | 2014 |
[Hypertensive patient with metabolic syndrome: would you prescribe a diuretic as the initial treatment? (interview by Thomas Meissner)].
Topics: Adrenergic alpha-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cal | 2008 |
Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent
Topics: Aged; Amlodipine; Antihypertensive Agents; Atherosclerosis; Blood Pressure; Chlorthalidone; Cohort S | 2008 |